Healthcare shares are higher in pre-market trade. In earnings
news, AVEO Pharmaceuticals (
) reported a Q2 loss of $0.62 per share, versus the Capital IQ
consensus of $0.55 loss per share. Revenues were $0.32 million,
versus the analyst estimate of $0.62 million.
In the same period last year, the company reported a loss per
share of $0.62 on revenues of $1.9 million. AVEO is flat in
pre-market at $2.27 per share.
Other news came from Sarepta Therapeutics (
), which said it plans to seek New Drug Approval from the U.S. FDA
for Eteplirsen in the first half of next year after positive
clinical study results. The drugs treat patients with Duchenne
muscular dystrophy (
) who have a genotype amenable to skipping of exon 51.
Published study results showed that once-weekly treatment with
eteplirsen resulted in a statistically significant increase in
novel dystrophin, a protein lacking in patients with DMD. In
addition, eteplirsen-treated patients on the 6-minute walk test
were more stable that those treated with a placebo. The shares are
up 0.6% at $37.10 in pre-market.
) is down 42.5% at $5.02 in the pre-market session after it swung
to a loss from a year prior. It reported a Q2 loss per share of
$0.37, better than the Capital IQ consensus estimate of $0.59 loss
per share. Revenues of $9.7 million missed the consensus of $10.8
In the same period last year, the company posted EPS of $0.32 on
revenues of $10.5 million.
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.